Session – Cell therapy transition challenges – Moving from early to late stage development With nearly 30 years of R&D experience Dr. Townson has led the development and commercialization of pharmaceutical and biotechnology products across numerous therapeutic areas in small and large global organizations. Prior to Bayer Dr. Townson served as the Cell and Gene Therapy Program Office Head at Novartis helping to bring Kymriah to patients. Dr. Townson currently serves as Program Head for immuno-oncology programs at Bayer working on both small molecule and antibody-based treatments.